5-HT3-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment

@article{Aapro20055HT3ReceptorAI,
  title={5-HT3-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment},
  author={M. Aapro},
  journal={Oncology},
  year={2005},
  volume={69},
  pages={109 - 97}
}
  • M. Aapro
  • Published 2005
  • Medicine
  • Oncology
    • The 5-HT3-receptor antagonists, considered as ‘gold standard’ therapy for cancer patients, are generally perceived to have similar efficacy and safety profiles, andmost antiemetic guidelines do not distinguish between agents. However, important pharmacological differences exist between agents, which may translate into potential benefits for some patients. In particular, 5-HT3-receptor antagonists vary in the nature of their receptor antagonism and plasma half-lives, possibly leading to… CONTINUE READING
    View via Publisher
    37 Citations
    Highly Influencial Citations
    1
    Background Citations
    8

    Figures, Tables, and Topics from this paper

    Figures and Tables

    Explore Further: Topics Discussed in This Paper

    37 Citations
    Citation Type

    Citation Type

    Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    • 2
    Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders.
    • 5
    Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia
    • 16
    • PDF
    Treatment of Nausea and Vomiting in Terminally I11 Cancer Patients
    • 53
    Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting
    • 15
    • PDF
    Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
    • T. Machu
    • Chemistry, Medicine
    • Pharmacology & therapeutics
    • 2011
    • 59
    Antiemetic placebo: reduce adverse drug interactions between chemotherapeutic agents and antiemetic drugs in cancer patients.
    • 11
    Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.
    • 13
    Palonosetron Hydrochloride in the Prevention and Treatment of Postoperative Nausea and Vomiting
    • 17
    • PDF
    Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting
    • 19

    References

    SHOWING 1-10 OF 112 REFERENCES
    5‐HT3‐Receptor Antagonists and the Cytochrome P450 System: Clinical Implications
    • 59
    Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    • N. Minton
    • Medicine
    • British journal of clinical pharmacology
    • 1994
    • 20
    Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
    • C. Lindley, P. Blower
    • Medicine
    • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
    • 2000
    • 34
    • PDF
    The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
    • 63
    • PDF
    Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
    • 224
    An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting.
    • 85
    Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients.
    • O. Koriech
    • Medicine
    • Clinical oncology (Royal College of Radiologists (Great Britain))
    • 1995
    • 29
    A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response
    • 70
    Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    • 12
    Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
    • 235